Abbott increases investment in SpectRx:
This article was originally published in Clinica
Abbott Laboratories has increased its shareholding in the non-invasive glucose monitor developer, SpectRx, of Norcross, Georgia, by buying $2.75 million in preferred shares with a further $2.5 million commitment in January under the same terms. The revised agreement for the continuous monitoring device, presently in prototype form, gives Abbott exclusive worldwide marketing rights. SpectRx gets new milestones and will get a royalty on disposables when the product is eventually launched.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.